Navigation Links
Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
Date:8/3/2009

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in relapsed or relapsed / refractory multiple myeloma patients previously treated with bortezomib (VELCADE((R))). The SPA provides agreement that the Phase 3 study design adequately addresses objectives in support of a regulatory submission. The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib" will be a double-blind, placebo-controlled trial comparing the efficacy and safety of KRX-0401 vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will enroll approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety.

Dr. Kenneth Anderson, Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, commented, "Perifosine holds great promise for multiple myeloma patients worldwide. We at Dana-Farber, along with our other collaborating multiple myeloma centers, are encouraged to see perifosine move into this final stage of testing, and look forward to working with Keryx on this exciting trial."

Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Study Chairman for the KRX-0401 Phase 3 trial, added, "Perifosine has shown considerable activity when combined with bortez
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
2. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
11. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Petersburg, FL (PRWEB) July 30, 2014 Phytceramides are ... how and why in her new book. , Today is the ... Phytoceramides: Anti Aging At Its Best . The book is also ... skin care book, but felt that Phytoceramides were so ... to bring out this focused book now," says Kathy Heshelow, founder ...
(Date:7/29/2014)... Dublin, Ireland (PRWEB) July 30, 2014 ... announced the successful completion of a Phase I trial ... Acid (DGLA). , This study was a randomized, placebo-controlled, ... to assess the safety, pharmacokinetics and effect of food ... confirmed the benign safety profile of DGLA following both ...
(Date:7/29/2014)... July 29, 2014 The Mesothelioma ... the Deadliest Cancer Coalition, led advocacy efforts among ... the newly established Congressional Caucus on the Deadliest Cancers. ... caucus now features the following 20 members: , Rep. Matt ... – May 2, 2014, Rep. Zoe Lofgren (CA-19) – June ...
(Date:7/29/2014)... they have discovered a chemical alteration in a single ... in larger studies, could give doctors a simple blood ... suicide. , The discovery, described online in The ... a gene involved in the function of the brain,s ... turning what might otherwise be an unremarkable reaction to ...
(Date:7/29/2014)... rich in soy may help feminine hearts, but timing ... Menopause , the journal of The North American ... diet of women in Asia, produces the least atherosclerosis. ... Asian migrants to North America, leads to just as ... to soy from a Western diet after menopause helps ...
Breaking Medicine News(10 mins):Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Soy may help women's hearts if they start early 2
... -- A new study finds that many American children aged ... they ride in cars -- a practice that could prove ... National Highway Traffic Safety Administration survey of nearly 900 drivers. ... 9-year-old passengers use seat belts and more than three-quarters of ...
... FRIDAY, Nov. 18 (HealthDay News) -- Although one in four ... of colon surgery, new research reveals these readmissions -- which ... The most common reason colorectal surgery patients return to ... published in the December issue of the journal Diseases ...
... computing system broke new ground earlier this year when it ... Now, The Scripps Research Institute is hoping to do something ... of the prize money from that tournament: Find a cure ... To that end, Scripps Research and IBM (NYSE: ...
... Nov. 18 (HealthDay News) -- A "tongue-tie" condition in infants ... many cases, an expert says. The condition, also known ... newborns. The most common type is easy to identify and ... tongue indentation at the front of the mouth. Another ...
... HealthDay Reporter , FRIDAY, Nov. 18 (HealthDay News) -- Those ... foods around. U.S. government health experts now encourage ... Weight Watchers, new system assigns no points to nearly all ... But, really, what,s the big deal? Why is it so ...
... rates due to colorectal cancer have declined overall, yet ... suggests that underuse of colonoscopy screening among these groups ... New York City launched a multifaceted campaign to improve ... A new study conducted by researchers at Columbia University,s ...
Cached Medicine News:Health News:Ill-Fitting Children's Seat Belts Common in U.S., Study Finds 2Health News:Colon Surgery Linked to High Readmission Rates 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 3Health News:Easy-to-Treat Condition Can Disrupt Breast-Feeding 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 4Health News:Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy 2Health News:Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy 3
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
(Date:7/29/2014)... 29, 2014  Sequenom, Inc. (NASDAQ: SQNM ... solutions, today reported total revenues of $39.8 million for ... compared to revenues of $24.5 million for the second ... segment, which was sold on May 30, 2014, has ... its results have been excluded from continuing operations for ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
Breaking Medicine Technology:Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... Corporation (NASDAQ: VOLC ), a leading developer and ... the diagnosis and treatment of coronary and peripheral vascular disease, ... the third quarter of fiscal 2011 on Monday, October 31. ... discuss its financial results and operating activities open to all ...
... 17, 2011 Archimedes Pharma Ltd., and its subsidiary, ... nasal spray is now available by prescription in U.S. ... pain in cancer patients 18 years of age and ... to opioid therapy for their underlying persistent cancer pain. ...
Cached Medicine Technology:Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7
For use with E5381 600 Circling Band (40 style). 2.2 mm diameter, 28.5 mm long....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: